Search Patents
  • Humanized anti-AXL antibodies
    Patent number: 11059893
    Abstract: The present disclosure relates to humanized anti-Axl antibodies.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: July 13, 2021
    Assignee: BERGENBIO ASA
    Inventors: Patricius Hendrikus Cornelis Van Berkel, David G. Williams
  • ANTI-AXL ANTIBODIES
    Publication number: 20170107290
    Abstract: Antibodies which specifically bind to the Ax I protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: June 18, 2015
    Publication date: April 20, 2017
    Applicant: BERGENBIO AS
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, Linn Hodneland NILSSON, Lavina AHMED, Hallvard HAUGEN
  • ANTI-AXL ANTIBODIES
    Publication number: 20180371096
    Abstract: Antibodies which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: April 20, 2018
    Publication date: December 27, 2018
    Applicant: BerGenBio ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, Linn Hodneland NILSSON, Lavina AHMED, Hallvard HAUGEN
  • ANTI-AXL ANTIBODIES
    Publication number: 20220185897
    Abstract: Antibodies which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: October 18, 2021
    Publication date: June 16, 2022
    Applicant: BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, Linn Hodneland Nilsson, Lavina Ahmed, Hallvard Haugen
  • Anti-Axl antibodies
    Patent number: 11186643
    Abstract: Antibodies which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: November 30, 2021
    Assignee: BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, Linn Hodneland Nilsson, Lavina Ahmed, Hallvard Haugen
  • Serum Biomarkers
    Publication number: 20210215697
    Abstract: The present disclosure relates to the field of cancer biomarkers and treatments, and more particularly to methods of predicting susceptibility to cancer treatments, in particular treatments with Axl inhibitors. Also disclosed are products, such as kits, having utility in performing the disclosed methods.
    Type: Application
    Filed: May 13, 2019
    Publication date: July 15, 2021
    Applicant: BerGenBio ASA
    Inventors: Robert Holt, David Micklem
  • Anti-Axl antibodies
    Patent number: 9975953
    Abstract: Antibodies which specifically bind to the Ax I protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: May 22, 2018
    Assignee: BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, Linn Hodneland Nilsson, Lavina Ahmed, Hallvard Haugen
  • ANTI-AXL ANTIBODIES
    Publication number: 20170129957
    Abstract: Antibodies characterized by their variable sequences/CDRs which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: June 18, 2015
    Publication date: May 11, 2017
    Applicant: BERGENBIO AS
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, Linn Hodneland NILSSON, Lavina AHMED, Hallvard HAUGEN
  • Anti-Axl antibodies
    Patent number: 9975954
    Abstract: Antibodies characterized by their variable sequences/CDRs which specifically bind to the Axl protein are described. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: May 22, 2018
    Assignee: BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, Linn Hodneland Nilsson, Lavina Ahmed, Hallvard Haugen
  • Anti-Axl Antagonistic Antibodies
    Publication number: 20220195054
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: November 2, 2021
    Publication date: June 23, 2022
    Applicants: BERGEN TEKNOLOGIOVERFØRING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn NILSSON, Tone SANDAL
  • Anti-Axl Antagonistic Antibodies
    Publication number: 20210171643
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: June 21, 2017
    Publication date: June 10, 2021
    Applicants: BERGEN TEKNOLOGIOVERFØRING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn NILSSON, Tone SANDAL
  • METHOD
    Publication number: 20200072839
    Abstract: The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity.
    Type: Application
    Filed: May 10, 2019
    Publication date: March 5, 2020
    Applicant: BERGENBIO ASA
    Inventors: Jim Lorens, Crina Tiron
  • BIOMARKERS FOR CANCER
    Publication number: 20180208989
    Abstract: The use of PHGDH as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of PHGDH modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring PHGDH expression and/or activity.
    Type: Application
    Filed: July 8, 2016
    Publication date: July 26, 2018
    Applicant: BERGENBIO ASA
    Inventors: Monica HELLESOY, Linn Hodneland NILSSON, David Robert MICKLEM
  • SLFN11 AS BIOMARKER FOR AML
    Publication number: 20170314077
    Abstract: The use of Slfn11 as a biomarker for detecting the occurrence of epithlial-to-mesenchymal transition (EMT) in a subject, and the use of Slfn11 modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Slfn11 expression and/or activity.
    Type: Application
    Filed: November 13, 2015
    Publication date: November 2, 2017
    Applicant: BERGENBIO AS
    Inventors: David Robert MICKLEM, Monica HELLESOY, Linn Hodneland NILSSON
  • ANTI-AXL ANTAGONISTIC ANTIBODIES
    Publication number: 20190177419
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: December 19, 2018
    Publication date: June 13, 2019
    Applicants: BERGEN TEKNOLOGIOVERFORING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn Hodneland NILSSON, Tone SANDAL
  • ANTI-AXL ANTAGONISTIC ANTIBODIES
    Publication number: 20170349658
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: December 18, 2015
    Publication date: December 7, 2017
    Applicants: BERGEN TEKNOLOGIOVERFORING AS, BERGENBIO AS
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn Hodneland NILSSON, Tone SANDAL
  • Anti-AXL Antagonistic Antibodies
    Publication number: 20230406941
    Abstract: Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Application
    Filed: February 17, 2023
    Publication date: December 21, 2023
    Applicants: BERGEN TEKNOLOGIOVERFØRING AS, BERGENBIO ASA
    Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn Hodneland NILSSON, Tone SANDAL
  • Biomarkers for cancer
    Patent number: 11035008
    Abstract: The use of PHGDH as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of PHGDH modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring PHGDH expression and/or activity.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: June 15, 2021
    Assignee: BerGenBio ASA
    Inventors: Monica Hellesoy, Linn Hodneland Nilsson, David Robert Micklem
  • Anti-Axl antagonistic antibodies
    Patent number: 11198734
    Abstract: The present disclosure relates to antibodies that specifically bind a novel epitope on the AxI protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: December 14, 2021
    Assignees: Bergen Teknologioverføring AS, BerGenBio ASA
    Inventors: David Robert Micklem, Sergej Kiprijanov, James Bradley Lorens, Lavina Ahmed, Linn Nilsson, Tone Sandal
  • AXL Inhibitors for Antiviral Therapy
    Publication number: 20230250169
    Abstract: This disclosure relates to compostions and methods for preventing and treating a viral infection in a subject. In particular, the present disclosure provides compostions and methods of preventing or treating infection of a subject with a coronavirus such as the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) that causes the disease COVID-19.
    Type: Application
    Filed: April 1, 2021
    Publication date: August 10, 2023
    Applicant: BERGENBIO ASA
    Inventors: James Bradley LORENS, Wendy MAURY
Narrow Results

Filter by US Classification